Related Experiment Video
Updated: Jul 16, 2026
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Long QT syndrome and pregnancy
Rahul Seth1, Arthur J Moss, Scott McNitt
1Cardiology Division of the Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA.
Journal of the American College of Cardiology
|March 14, 2007
Summary
Women with long QT syndrome (LQTS) face lower cardiac event risks during pregnancy but higher risks in the postpartum period. Beta-blocker therapy can mitigate these postpartum risks, particularly for LQT2 genotypes.
Area of Science:
- Cardiology
- Genetics
- Reproductive Health
Background:
- Limited data exist on pregnancy risks for women with long QT syndrome (LQTS).
- Understanding peripartum cardiac event risks is crucial for managing LQTS in women of childbearing age.
Purpose of the Study:
- To investigate the clinical course and cardiac event risks for women with long QT syndrome (LQTS) during their childbearing years.
- To analyze peripartum cardiac event risks in relation to LQTS genotype and therapeutic interventions.
Main Methods:
- Retrospective analysis of 391 women with LQTS experiencing their first birth (1980-2003).
- Time-dependent Kaplan-Meier and Cox proportional hazard models used to assess cardiac event risks.
- Genotype analysis performed on 153 women to correlate specific LQTS types with event risk.
Main Results:
- Pregnancy was associated with a reduced risk of cardiac events (HR 0.28), while the 9-month postpartum period showed an increased risk (HR 2.7).
- The LQT2 genotype presented a higher risk of cardiac events compared to LQT1 or LQT3.
- Beta-blocker therapy significantly reduced cardiac event risk during the high-risk postpartum period (HR 0.34).
Conclusions:
- Women with LQTS experience decreased cardiac event risk during pregnancy but elevated risk in the 9-month postpartum period.
- The LQT2 genotype is associated with higher postpartum cardiac event risk.
- Beta-blockers are effective in reducing cardiac events during the high-risk postpartum period for women with LQTS.
Related Concept Videos
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...